Sign In
Section Navigation
Common TitleACTG 229
Official Title Double-Blind, Randomized, Phase II Study of Saquinavir (Ro 31-8959) Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Saquinavir (Ro 31-8959) Plus AZT Plus ddC
Phase Phase II
ClinicalTrials.gov NCT00001040
Categories Treatment-ExperiencedDual TherapyResistance/Virological FailurePharmacologyGeneral Pharmacology
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
  • Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-7.
    [PubMed Abstract]
  • Schapiro JM, Lawrence J, Speck R, et al. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis. 1999;179:249-53.
    [PubMed Abstract]
  • Vanhove GF, Gries JM, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41:2433-8.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.